Patent applications published 24 February 2010
Patent applications taken from the weekly European Patents Bulletin
- Treatment of cardiovascular disease and dyslipidaemia using secretory phospholipidase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
Anthera Pharmaceuticals 2154958*
- Stable non-aqueous pour-on compsns
Wyeth 2154960*
- Antimicrobial compsn and method for making and using same
Bioneutral Laboratories 2154961*
- Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
Sepracor 2154962*
- Iminopyrrolidone thiol amino acid conjugates, pharmaceutical compsn and methods for the treatment of cancer
The Arizona Board of Regents on behalf of the University of Arizona 2154963*
- Naphthyridine, derivatives as P13 kinase inhibitors
GlaxoSmithKline 2154965*
- Benzimidazoles and pharmaceutical compsns thereof
The Research Foundation of State University of New York 2154966*
- Pyrimidine derivatives
Hutchison Medipharma Enterprises 2154967*
- Treatment of synucleinopathies
The Brigham and Women's Hospital 2154969*
- Disubstituted amides for enhancing glutamatergic synaptic responses
Cortex Pharmaceuticals 2154970*
- A synergistic pharmaceutical combination for the treatment of cancer
Piramal Life Sciences 2154971*
- Compsn for injection including propofol and method of preparing the same
Dae Won Pharmaceutical 2155163*
- Self-precipitating pharmaceutical formulations for th modified release of active principle
Flamel Technologies 2155164*
- Drug delivery vehicle containing vesicles in a hydrogel base
BioCure; Hirt, Thomas; Meier, Wolfgang; Lu, Zhihua; Hu, Xianbo 2155165*
- Pharmaceutical compsn for poorly soluble drugs
F Hoffmann-La Roche 2155166*
- Controlled release pharmaceutical compsns for prolonged effect
Egalet 2155167*
- Stable pharmaceutical compsns of clopidogrel bisulfate and process of preparation thereof
USV 2155168*
- Extended release formulation of nevirapine
Boehringer Ingelheim International 2155169*
- Extended release formulation and method of treating adrenergic dysregulation
Addrenex Pharmaceuticals 2155170*
- Osmotic form for controlled release of active principles
Libbs Farmaceutica 2155171*
- Gastroretentive system comprising an alginate body
LTS Lohmann Therapie-Systeme 2155172*
- Modified-release particles based on polyelectrolytes and on an active principle and pharmaceutical formulations containing these particles
Flamel Technologies 2155173*
- Uniformly abrasive confectionary product and process therefor
Breezy Industries 2155174*
- Matrix-type transdermal drug delivery system and preparation method thereof
Samyang Corp 2155175*
- Substrate promoting angiogenesis
Gelita 2155176*
- Modification of biological targeting groups for the treatment of cancer
Intezyne Technologies 2155177*
- Spiro compounds for treatment of inflammatory disorders
Salutria Pharmaceuticals 2155178*
- Axomadol for treating pain from arthritis
Gruenenthal 2155179*
- Drug compound and its use in the treatment of muscle loss
Acacia Pharma 2155180*
- 5-HTP combination therapy
H Lundbeck 2155181*
- Novel compsns comprising a phosphodiesterase-5 inhibitor and their use in methods of treatment
Vivus 2155182*